Immatics N.V. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
IMTX Nasdaq 2834 www.immatics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immatics N.V.

Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Nov 20th, 2024 11:59 am
Immatics Sees Revenue Surge Despite R&D Expenses - Nov 19th, 2024 12:25 pm
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - Nov 18th, 2024 12:00 pm
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - Nov 8th, 2024 10:00 pm
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% - Oct 23rd, 2024 11:11 am
Immatics Advances IMA203 to Phase 3 Trial in Melanoma - Oct 11th, 2024 10:57 am
Immatics Announces Pricing of $150 Million Public Offering - Oct 11th, 2024 12:50 am
Immatics Announces Proposed $150 Million Public Offering - Oct 10th, 2024 11:30 am
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial - Oct 10th, 2024 10:30 am
Immatics N.V. (IMTX) Receives Buy Rating from Analysts - Oct 9th, 2024 12:03 pm
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 - Oct 4th, 2024 1:00 pm
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update - Sep 16th, 2024 9:25 am
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 - Sep 6th, 2024 11:00 am
Immatics Second Quarter 2024 Earnings: Beats Expectations - Aug 15th, 2024 10:37 am
Immatics Announces Second Quarter 2024 Financial Results and Business Update - Aug 13th, 2024 11:00 am
Immatics Appoints Alise Reicin to Board of Directors - Jul 31st, 2024 11:00 am
Investors in Immatics (NASDAQ:IMTX) have seen returns of 24% over the past five years - Jul 25th, 2024 10:12 am
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 - Jul 18th, 2024 1:00 pm
Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns - Jun 14th, 2024 11:40 am
Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation - May 21st, 2024 12:44 pm